Nordic Nanovector ASA News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.06.19	Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL (PR Newswire)
03.06.19	Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL (PR Newswire)
31.05.19	Nordic Nanovector ASA: Increase of Share Capital (PR Newswire)
31.05.19	Nordic Nanovector ASA: Increase of Share Capital (PR Newswire)
27.05.19	Nordic Nanovector to Present at Redeye Pre-ASCO Seminar, Jefferies Healthcare Conference and ABGSC Oncology Seminar (PR Newswire)
27.05.19	Nordic Nanovector to Present at Redeye Pre-ASCO Seminar, Jefferies Healthcare Conference and ABGSC Oncology Seminar (PR Newswire)
23.05.19	Nordic Nanovector ASA - Allocation of PSUs (PR Newswire)
23.05.19	Nordic Nanovector ASA - Allocation of PSUs (PR Newswire)
23.05.19	Nordic Nanovector ASA - Results for the First Quarter 2019 (PR Newswire)
23.05.19	Nordic Nanovector ASA - Results for the First Quarter 2019 (PR Newswire)
21.05.19	Nordic Nanovector: Archer-1 Phase 1b Betalutin®/Rituximab Combination Trial Advances to Next Cohort (PR Newswire)
21.05.19	Nordic Nanovector: Archer-1 Phase 1b Betalutin®/Rituximab Combination Trial Advances to Next Cohort (PR Newswire)
16.05.19	Nordic Nanovector ASA: Invitation to First Quarter 2019 Results Presentation and Webcast (PR Newswire)
16.05.19	Nordic Nanovector ASA: Invitation to First Quarter 2019 Results Presentation and Webcast (PR Newswire)
10.05.19	Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors (PR Newswire)
10.05.19	Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors (PR Newswire)
29.04.19	Nordic Nanovector Appoints Fredrik Haavind as Head of Legal and Compliance (PR Newswire)
29.04.19	Nordic Nanovector Appoints Fredrik Haavind as Head of Legal and Compliance (PR Newswire)
25.04.19	Nordic Nanovector ASA: Annual General Meeting Held (PR Newswire)
25.04.19	Nordic Nanovector ASA: Annual General Meeting Held (PR Newswire)
10.04.19	Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL (PR Newswire)
10.04.19	Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL (PR Newswire)
04.04.19	Nordic Nanovector ASA: Notice of Annual General Meeting on 25 April 2019 (PR Newswire)
04.04.19	Nordic Nanovector ASA: Notice of Annual General Meeting on 25 April 2019 (PR Newswire)
03.04.19	Nordic Nanovector ASA Publishes 2018 Annual Report (PR Newswire)
03.04.19	Nordic Nanovector ASA Publishes 2018 Annual Report (PR Newswire)
02.04.19	Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11 (PR Newswire)
02.04.19	Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11 (PR Newswire)
28.03.19	Nordic Nanovector to Present at DNB's SME Conference and Kempen Life Science Conference (PR Newswire)
28.03.19	Nordic Nanovector to Present at DNB's SME Conference and Kempen Life Science Conference (PR Newswire)
18.03.19	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
18.03.19	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
14.03.19	Nordic Nanovector ASA - Share Capital Increase Registered (PR Newswire)
14.03.19	Nordic Nanovector ASA - Share Capital Increase Registered (PR Newswire)
12.03.19	Financial Calendar for Nordic Nanovector ASA (PR Newswire)
12.03.19	Financial Calendar for Nordic Nanovector ASA (PR Newswire)
11.03.19	Nordic Nanovector to Attend Cowen Health Care Conference, BioCapital Europe and Stifel Nordic Healthcare Seminar (PR Newswire)
11.03.19	Nordic Nanovector to Attend Cowen Health Care Conference, BioCapital Europe and Stifel Nordic Healthcare Seminar (PR Newswire)
06.03.19	Nordic Nanovector ASA - Final Result of the Repair Offering (PR Newswire)
06.03.19	Nordic Nanovector ASA - Final Result of the Repair Offering (PR Newswire)
04.03.19	Nordic Nanovector ASA: Increase of Share Capital (PR Newswire)
27.02.19	Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2018 (PR Newswire)
27.02.19	Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2018 (PR Newswire)
20.02.19	Nordic Nanovector ASA: Prospectus Approved and Repair Offering (PR Newswire)
20.02.19	Nordic Nanovector ASA: Prospectus Approved and Repair Offering (PR Newswire)
20.02.19	Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast (PR Newswire)
20.02.19	Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast (PR Newswire)
18.02.19	Nordic Nanovector ASA: Extraordinary General Meeting Held (PR Newswire)
18.02.19	Nordic Nanovector ASA: Extraordinary General Meeting Held (PR Newswire)
30.01.19	Nordic Nanovector ASA - Registration of Share Capital Increase in the Norwegian Register of Business Enterprises (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nordic Nanovector ASA

Aktien Top/Flop

Meistgelesene Nachrichten